ICU Medical (NASDAQ:ICUI) Reaches New 1-Year High – What’s Next?

ICU Medical, Inc. (NASDAQ:ICUI) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $166.12 and last traded at $167.8310, with a volume of 4195 shares changing hands. The stock had previously closed at $161.46.

Analyst Upgrades and Downgrades

ICUI has been the topic of several research analyst reports. BTIG Research initiated coverage on ICU Medical in a research report on Monday, June 15th. They issued a “buy” rating and a $170.00 price objective on the stock. Zacks Research raised ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a report on Monday, June 15th. Finally, Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Three investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $172.00.

ICU Medical Stock Up 2.9%

The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The stock has a 50-day simple moving average of $144.98 and a 200-day simple moving average of $139.78. The firm has a market capitalization of $4.15 billion, a PE ratio of 89.95, a P/E/G ratio of 2.20 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.78 by $0.19. The firm had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business’s revenue was down 12.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Analysts forecast that ICU Medical, Inc. will post 6.51 EPS for the current year.

Insider Transactions at ICU Medical

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares in the company, valued at $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

A number of institutional investors have recently modified their holdings of the business. AQR Capital Management LLC grew its stake in ICU Medical by 2.5% in the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after buying an additional 229 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of ICU Medical by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after acquiring an additional 560 shares in the last quarter. United Services Automobile Association bought a new position in shares of ICU Medical in the first quarter worth $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of ICU Medical by 32.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after acquiring an additional 16,680 shares during the period. Finally, Intech Investment Management LLC grew its position in shares of ICU Medical by 38.6% in the first quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock valued at $1,658,000 after purchasing an additional 3,326 shares in the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.